Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Shares of AbbVie Inc. ABBV rose 1.79% to $200.88 Thursday, on what proved to be an all-around poor trading session for the ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

Having kicked off the year with a T-cell engager deal, AbbVie has returned to the modality. | Having kicked off the year with ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.64, payable on Friday, Feb.

The North Chicago drugmaker says it could pay Xilio Therapeutics more than $2.1 billion in a collaboration and ...

AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...